306 related articles for article (PubMed ID: 31454530)
1. Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG.
McSweeney MD; Price LSL; Wessler T; Ciociola EC; Herity LB; Piscitelli JA; DeWalle AC; Harris TN; Chan AKP; Saw RS; Hu P; Jennette JC; Forest MG; Cao Y; Montgomery SA; Zamboni WC; Lai SK
J Control Release; 2019 Oct; 311-312():138-146. PubMed ID: 31454530
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice.
McSweeney MD; Shen L; DeWalle AC; Joiner JB; Ciociola EC; Raghuwanshi D; Macauley MS; Lai SK
J Control Release; 2021 Jan; 329():774-781. PubMed ID: 33038448
[TBL] [Abstract][Full Text] [Related]
3. A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse.
McSweeney MD; Wessler T; Price LSL; Ciociola EC; Herity LB; Piscitelli JA; Zamboni WC; Forest MG; Cao Y; Lai SK
J Control Release; 2018 Aug; 284():171-178. PubMed ID: 29879519
[TBL] [Abstract][Full Text] [Related]
4. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
[TBL] [Abstract][Full Text] [Related]
5. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
6. [Recent advances in the study of accelerated blood clearance phenomenon of PEGylated liposomes].
Xu H; Wang KQ; Huang WW; Deng YH; Chen DW
Yao Xue Xue Bao; 2010 Jun; 45(6):677-83. PubMed ID: 20939173
[TBL] [Abstract][Full Text] [Related]
7. A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes.
El Sayed MM; Shimizu T; Abu Lila AS; Elsadek NE; Emam SE; Alaaeldin E; Kamal A; Sarhan HA; Ando H; Ishima Y; Ishida T
Int J Pharm; 2022 Mar; 615():121539. PubMed ID: 35124114
[TBL] [Abstract][Full Text] [Related]
8. A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes.
Talkington AM; McSweeney MD; Wessler T; Rath MK; Li Z; Zhang T; Yuan H; Frank JE; Forest MG; Cao Y; Lai SK
J Control Release; 2022 Mar; 343():518-527. PubMed ID: 35066099
[TBL] [Abstract][Full Text] [Related]
9. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice.
Hashimoto Y; Shimizu T; Abu Lila AS; Ishida T; Kiwada H
Biol Pharm Bull; 2015; 38(3):417-24. PubMed ID: 25757923
[TBL] [Abstract][Full Text] [Related]
10. Attenuated polyethylene glycol immunogenicity and overcoming accelerated blood clearance of a fully PEGylated dendrimer.
Kojima C; Yao J; Nakajima K; Suzuki M; Tsujimoto A; Kuge Y; Ogawa M; Matsumoto A
Int J Pharm; 2024 Jun; 659():124193. PubMed ID: 38703934
[TBL] [Abstract][Full Text] [Related]
11. Free PEG Suppresses Anaphylaxis to PEGylated Nanomedicine in Swine.
Shen L; Li Z; Ma A; Cruz-Teran C; Talkington A; Shipley ST; Lai SK
ACS Nano; 2024 Mar; 18(12):8733-8744. PubMed ID: 38469811
[TBL] [Abstract][Full Text] [Related]
12. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
13. Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein.
Mima Y; Hashimoto Y; Shimizu T; Kiwada H; Ishida T
Mol Pharm; 2015 Jul; 12(7):2429-35. PubMed ID: 26070445
[TBL] [Abstract][Full Text] [Related]
14. Pegloticase co-administered with high MW polyethylene glycol effectively reduces PEG-immunogenicity and restores prolonged circulation in mouse.
Li Z; Shen L; Ma A; Talkington A; Li Z; Nyborg AC; Bowers MS; LaMoreaux B; Livingston EW; Frank JE; Yuan H; Lai SK
Acta Biomater; 2023 Oct; 170():250-259. PubMed ID: 37659730
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection.
Laverman P; Carstens MG; Boerman OC; Dams ET; Oyen WJ; van Rooijen N; Corstens FH; Storm G
J Pharmacol Exp Ther; 2001 Aug; 298(2):607-12. PubMed ID: 11454922
[TBL] [Abstract][Full Text] [Related]
16. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
17. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats.
Subasic CN; Butcher NJ; Minchin RF; Kaminskas LM
Mol Pharm; 2023 Jul; 20(7):3494-3504. PubMed ID: 37256791
[TBL] [Abstract][Full Text] [Related]
18. Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes.
Hsieh YC; Wang HE; Lin WW; Roffler SR; Cheng TC; Su YC; Li JJ; Chen CC; Huang CH; Chen BM; Wang JY; Cheng TL; Chen FM
Theranostics; 2018; 8(11):3164-3175. PubMed ID: 29896310
[No Abstract] [Full Text] [Related]
19. Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives.
Gaballa SA; Shimizu T; Ando H; Takata H; Emam SE; Ramadan E; Naguib YW; Mady FM; Khaled KA; Ishida T
J Pharm Sci; 2024 Mar; 113(3):555-578. PubMed ID: 37931786
[TBL] [Abstract][Full Text] [Related]
20. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs.
Hashimoto Y; Shimizu T; Mima Y; Abu Lila AS; Ishida T; Kiwada H
Toxicol Appl Pharmacol; 2014 May; 277(1):30-8. PubMed ID: 24632081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]